Xuyuan Li1, Sujuan Zhu2, Chaoqun Hong3, Haoquan Cai4. 1. a a Department of Medical Oncology , Affiliated Shantou Hospital of Sun Yat-sen University , Shantou , Guangdong , China. 2. b b Department of Good Clinical Practice , Cancer Hospital of Shantou University Medical College , Shantou , Guangdong , China. 3. c c Cancer Research Lab, Cancer Hospital of Shantou University Medical College , Shantou , Guangdong , China. 4. d d Department of Medical Oncology , First affiliated Hospital of Shantou University Medical College , Shantou , Guangdong , China.
Abstract
OBJECTIVES: To investigate the effects of angiogenesis inhibitors in the treatment of patients with advanced or recurrent ovarian cancer, a meta-analysis was performed and overall survival (OS), progression-free survival (PFS), and toxicity were assessed. PATIENTS AND METHODS: The PubMed and Embase databases, and the Cochrane Central Register of Controlled Trials were searched for publications between January 2000 and June 2015. Hazard ratios (HRs) with their 95% confidence intervals (CIs), or data for calculating HRs with 95% CIs were derived. RESULTS: The 12 trials in this meta-analysis were divided into three groups: four trials with a VEGF inhibitor (the bevacizumab group), six trials with VEGFR inhibitors (the VEGFRIs group), and two trials with an angiopoietin inhibitor (the trebananib group). PFS improvement was seen in all groups (HR = 0.61, 95% CI 0.48 to 0.79, P < 0.001 for bevacizumab; HR = 0.71, 95% CI 0.59 to 0.87, P = 0.001 for VEGFRIs; and HR = 0.67, 95% CI 0.62 to 0.72, P < 0.001 for trebananib). Regarding OS, bevacizumab showed a trend of improvement (HR = 0.90, 95% CI 0.80 to 1.01, P = 0.079), VEGFRIs showed no improvement (HR = 0.92, 95% CI 0.75 to 1.11, P = 0.368), and trebananib demonstrated a significant prolongation (HR = 0.81, 95% CI 0.67 to 0.99, P = 0.036). Bevacizumab was associated with more class-specific adverse events (RR = 4.05, 95% CI 1.99 to 8.27, P < 0.001). Although the toxicity profiles differed, VEGFRIs developed common higher incidences of hypertension, diarrhea, and fatigue. A higher incidence of edema was reported in the trebananib group (RR = 2.60, 95% CI 0.84 to 8.00, P = 0.097). CONCLUSIONS: Anti-angiogenic therapy showed clear PFS benefit with increased toxicity, but its role in OS was undefined for ovarian cancer which emphasized the need for patient selection.
OBJECTIVES: To investigate the effects of angiogenesis inhibitors in the treatment of patients with advanced or recurrent ovarian cancer, a meta-analysis was performed and overall survival (OS), progression-free survival (PFS), and toxicity were assessed. PATIENTS AND METHODS: The PubMed and Embase databases, and the Cochrane Central Register of Controlled Trials were searched for publications between January 2000 and June 2015. Hazard ratios (HRs) with their 95% confidence intervals (CIs), or data for calculating HRs with 95% CIs were derived. RESULTS: The 12 trials in this meta-analysis were divided into three groups: four trials with a VEGF inhibitor (the bevacizumab group), six trials with VEGFR inhibitors (the VEGFRIs group), and two trials with an angiopoietin inhibitor (the trebananib group). PFS improvement was seen in all groups (HR = 0.61, 95% CI 0.48 to 0.79, P < 0.001 for bevacizumab; HR = 0.71, 95% CI 0.59 to 0.87, P = 0.001 for VEGFRIs; and HR = 0.67, 95% CI 0.62 to 0.72, P < 0.001 for trebananib). Regarding OS, bevacizumab showed a trend of improvement (HR = 0.90, 95% CI 0.80 to 1.01, P = 0.079), VEGFRIs showed no improvement (HR = 0.92, 95% CI 0.75 to 1.11, P = 0.368), and trebananib demonstrated a significant prolongation (HR = 0.81, 95% CI 0.67 to 0.99, P = 0.036). Bevacizumab was associated with more class-specific adverse events (RR = 4.05, 95% CI 1.99 to 8.27, P < 0.001). Although the toxicity profiles differed, VEGFRIs developed common higher incidences of hypertension, diarrhea, and fatigue. A higher incidence of edema was reported in the trebananib group (RR = 2.60, 95% CI 0.84 to 8.00, P = 0.097). CONCLUSIONS: Anti-angiogenic therapy showed clear PFS benefit with increased toxicity, but its role in OS was undefined for ovarian cancer which emphasized the need for patient selection.
Authors: Michael Yamakawa; Susan J Doh; Samuel M Santosa; Mario Montana; Ellen C Qin; Hyunjoon Kong; Kyu-Yeon Han; Charles Yu; Mark I Rosenblatt; Andrius Kazlauskas; Jin-Hong Chang; Dimitri T Azar Journal: Med Res Rev Date: 2018-03-12 Impact factor: 12.944
Authors: Aya El Helali; Charlene H L Wong; Horace C W Choi; Wendy W L Chan; Naomi Dickson; Steven W K Siu; Karen K Chan; Hextan Y S Ngan; Roger K C Ngan; Richard D Kennedy Journal: Sci Rep Date: 2022-03-09 Impact factor: 4.379
Authors: Swati Shrestha; Jia Shen; Paulina Giacomelli; Michelle A Scott; Chia Soo; Kang Ting; Bruno Péault; Sarah M Dry; Aaron W James Journal: J Orthop Date: 2016-11-28
Authors: Maggie K S Tang; Patrick Y K Yue; Philip P Ip; Rui-Lan Huang; Hung-Cheng Lai; Annie N Y Cheung; Ka Yu Tse; Hextan Y S Ngan; Alice S T Wong Journal: Nat Commun Date: 2018-06-11 Impact factor: 14.919